Medulloblastoma Gene-Edited Cell Lines for Drug Discovery

Medulloblastoma is the most common malignant brain tumor in children, accounting for approximately 20% of all pediatric central nervous system tumors. According to the World Health Organization (WHO) classification, the global incidence is estimated at 0.5-1.0 per 100,000 children under 15 years of age, with a peak incidence between 5-9 years. The National Cancer Institute (NCI) reports that the 5-year survival rate for medulloblastoma varies significantly by risk group: standard-risk patients have a survival rate of approximately 70-80%, while high-risk patients (including those with metastatic disease or residual tumor after surgery) have a 5-year survival rate of 50-60%. Key risk factors include germline mutations in genes such as APC (Turcot syndrome), TP53 (Li-Fraumeni syndrome), and SUFU (Gorlin syndrome). The disease is classified into four molecular subgroups: WNT, SHH, Group 3, and Group 4, each with distinct clinical outcomes and therapeutic vulnerabilities.

Medulloblastoma is an ideal model for mechanistic studies due to its well-defined molecular subgroups, availability of large public datasets (TCGA, cBioPortal, GEO), and established cell lines representing each subgroup. Open questions include the cellular origin of Group 3 and Group 4 tumors, mechanisms of therapy resistance, and the role of the tumor microenvironment. Gene-edited cell models are essential tools for dissecting these questions, enabling precise manipulation of driver genes and pathways.

Medulloblastoma arises from disrupted developmental signaling pathways in the cerebellum. The four major pathways are:

• • WNT pathway: Activation via CTNNB1 mutations or APC loss leads to nuclear beta-catenin accumulation and transcription of pro-proliferative genes.
• • SHH pathway: Mutations in PTCH1, SMO, or SUFU cause constitutive activation of the Sonic Hedgehog signaling cascade, promoting granule neuron precursor proliferation.
• • Group 3 pathway: Characterized by MYC amplification and OTX2 overexpression, driving a stem-like, aggressive phenotype.
• • Group 4 pathway: Associated with KDM6B and SNCAIP mutations, though the exact signaling network remains less defined.

Data sourced from TCGA and COSMIC databases.

Key signaling networks deregulated in medulloblastoma include:

• • WNT/beta-catenin pathway: Nuclear beta-catenin drives transcription of MYC and CCND1.
• • SHH pathway: PTCH1 loss leads to SMO activation, GLI transcription factor activity, and target gene expression (e.g., MYCN, BCL2).
• • PI3K/AKT/mTOR pathway: Frequently activated in SHH and Group 3 tumors, promoting cell survival and growth.
• • MYC/MYCN transcriptional network: Drives ribosome biogenesis, metabolism, and cell cycle progression.
• • NOTCH pathway: Involved in maintaining cancer stem cell populations in Group 3 tumors.

Commonly used medulloblastoma cell lines include:

Organoid models derived from patient tumors (patient-derived organoids, PDOs) offer advantages such as preservation of tumor heterogeneity, 3D architecture, and microenvironment interactions. They are increasingly used for drug screening and personalized medicine studies.

Animal models for medulloblastoma include:

• • Patient-derived xenografts (PDX): Implantation of patient tumor cells into immunodeficient mice; recapitulates tumor heterogeneity and drug response.
• • Genetically engineered mouse models (GEMM): Examples include Ptch1+/- mice (SHH subgroup), Math1-Cre; SmoM2 mice (SHH subgroup), and Gfap-Cre; Ctnnb1(ex3) mice (WNT subgroup).
• • Induced models: Orthotopic injection of gene-edited cells (e.g., MYC-overexpressing cerebellar stem cells) into mice to generate Group 3-like tumors.

CRISPR-based gene editing enables the generation of isogenic cell lines with precise genetic modifications. Examples include:

• • TP53 knockout in DAOY cells to study loss of tumor suppressor function in SHH medulloblastoma.
• • CTNNB1 G34V knock-in in WNT subgroup cells to model constitutive WNT activation.
• • MYC overexpression in cerebellar stem cells to generate Group 3-like models.
• • PTCH1 knockout in normal cerebellar cells to study SHH pathway activation.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing ready-to-use tools for functional studies, drug screening, and target validation. These models are generated using CRISPR-Cas9 technology and are validated by Sanger sequencing and functional assays.

Gene-edited cell lines are used to validate the role of specific genes in medulloblastoma pathogenesis. For example:

• • TP53 knockout in DAOY cells demonstrates increased resistance to DNA-damaging agents and enhanced tumorigenicity in vivo.
• • CTNNB1 knock-in in WNT subgroup cells confirms the role of beta-catenin stabilization in promoting proliferation and invasion.
• • MYC overexpression in normal cerebellar cells induces a stem-like phenotype and accelerates tumor formation in orthotopic models.

Isogenic cell pairs (e.g., TP53 wild-type vs. knockout) are used in drug screening to identify compounds that selectively target mutant cells. For example:

• • TP53-null medulloblastoma cells show increased sensitivity to CHK1 inhibitors, suggesting a synthetic lethal vulnerability.
• • MYC-amplified cells are more sensitive to BET bromodomain inhibitors (e.g., JQ1) compared to isogenic controls.
• • Resistance modeling: Chronic exposure of gene-edited cells to targeted therapies (e.g., SMO inhibitors in SHH models) can identify acquired resistance mutations.

CRISPR-based screens using gene-edited cell libraries can identify synthetic lethal interactions and biomarkers. For example:

• • A genome-wide CRISPR screen in MYC-amplified medulloblastoma cells identified WRN as a synthetic lethal target.
• • Loss-of-function screens in SHH subgroup cells revealed GLI1 as a critical dependency, suggesting it as a biomarker for SMO inhibitor sensitivity.
• • Isogenic models with specific mutations (e.g., CTNNB1 G34V) are used to identify downstream biomarkers for WNT subgroup classification.